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Abstract: OBJECTIVES Lung volume reduction (LVR) is an efficient and approved treatment for selected
emphysema patients. There is some evidence that repeated LVR surgery (LVRS) might be beneficial, but
there are no current data on LVRS after unsuccessful bronchoscopic LVR (BLVR) with endobronchial
valves (EBVs). We hypothesize good outcome of LVRS after BLVR with valves. METHODS In this study,
we retrospectively investigated all patients who underwent LVRS between 2015 and 2019 at 2 centres
after previous unsuccessful EBV treatment. They were further divided into subgroups with patients
who never achieved the intended improvement after BLVR (primary failure) and patients whose benefit
was fading over time due to the natural development of emphysema (secondary failure). Patients with
severe air leak after BLVR and immediate concomitant LVRS and fistula closure thereafter were analysed
separately. RESULTS A total of 38 patients were included. Of these, 19 patients had primary failure, 15
secondary failure and 4 were treated as an emergency due to severe air leak. At 3 months after LVRS,
forced expiratory volume in 1 s had improved significantly by 12.5% (P = 0.011) and there was no 90-day
mortality. Considering subgroups, patients with primary failure after BLVR seem to profit more than
those with secondary failure. Patients with severe air leak after BLVR did not profit from fistula closure
with concomitant LVRS. CONCLUSIONS LVRS after previous BLVR with EBVs can provide significant
clinical improvement with low morbidity, although results might not be as good as after primary LVRS.
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Visual abstract 26 
Key question: Is salvage lung volume reduction surgery (LVRS) reasonable after 27 
bronchoscopic lung volume reduction (BLVR) with valves? 28 
Key findings: LVRS after BLVR with valves showed significant improvement of lung function 29 
with low morbidity and no mortality.  30 
Take-home message: LVRS after previous BLVR with valves is reasonable at least as 31 
salvage procedure. 32 
 33 
Central image 34 
 35 
 36 
Figure legend for Central image:  37 
Bilateral, upper-lobe predominant emphysema: coronal CT scan (left upper corner), sagittal 38 
densitometry of the right lung (right upper corner), endobronchial valve in situ (left lower 39 





Objectives:  43 
Lung volume reduction is an efficient and approved treatment for selected emphysema 44 
patients. There is some evidence, that repeated LVR surgery (LVRS) might be beneficial, but 45 
there are no current data on LVRS after unsuccessful bronchoscopic LVR (BLVR) with 46 
endobronchial valves (EBVs). We hypothesize good outcome of LVRS after BLVR with 47 
valves.    48 
Methods:  49 
In this study, we retrospectively investigated all patients who underwent LVRS between 2015 50 
and 2019 at two centers after previous unsuccessful EBV treatment. They were further 51 
devided into subgroups with patients who never achieved the intended improvement after 52 
BLVR (primary failure), and patients whose benefit was fading over time due to the natural 53 
development of emphysema (secondary failure). Patients with severe air leak after BLVR 54 
and immediate concomitant LVRS and fistula closure thereafter were analyzed separately.  55 
Results:  56 
A total of 38 patients were included. Of these, 19 patients had primary failure, 15 secondary 57 
failure and four were treated as an emergency due to severe air leak. At three months after 58 
LVRS, FEV1 had improved significantly by 12.5% (P=0.011) and there was no 90- day 59 
mortality. Considering subgroups, patients with primary failure after BLVR seem to profit 60 
more than those with secondary failure. Patients with severe air leak after BLVR did not profit 61 
from fistula closure with concomitant LVRS. 62 
Conclusions: 63 
LVRS after previous BLVR with EBVs can provide significant clinical improvement with low 64 
morbidity, although results might not be as good as after primary LVRS. 65 
 66 
Key words:  67 




Lung volume reduction (LVR) has been established as a beneficial and safe procedure in 70 
patients with pulmonary emphysema and hyperinflation. Lung volume reduction surgery 71 
(LVRS) and bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBVs), 72 
coils or bronchial thermal vapor ablation (BTVA) are available (1-3). All methods have been 73 
demonstrated to improve lung function, exercise capacity and quality of life in patients with 74 
both heterogeneous and homogeneous emphysema (4-7). LVRS and BLVR with EBVs have 75 
both been shown to prolong survival in highly selected patients (7, 8). For selection of patients 76 
and the optimal LVR procedure, it is recommendable to establish multidisciplinary conferences 77 
(9, 10).  78 
However, chronic obstructive pulmonary disease (COPD) is a progressive disease and neither 79 
LVR procedure is able to stop the natural course with an annual lung function decline and 80 
recurring  hyperinflation (11). Therefore, initially successful LVR treatment effects may diminish 81 
over months or years (4, 12, 13). Repeated LVRS (Re-LVRS) shows promising results in highly 82 
selected patients, who are slowly deteriorating after initially successful LVRS (14, 15). Once a 83 
patient who already had LVR with EBVs is referred, LVRS might be offered.  84 
To the best of our knowledge, there are so far no reports on LVRS after BLVR.  85 
In this retrospective study from two European centers, we aimed to investigate LVRS after 86 
previous BLVR with EBVs with focus on mortality, morbidity and outcome.  87 
 88 
Patients and Methods 89 
Ethical approval 90 
This study was performed under both institutional board’s ethical approval. 91 
 92 
All patients with previous BVLR with EBVs, who underwent LVRS at one of the two study 93 
centers (Department of Thoracic Surgery, University Hospital Zurich, Switzerland and 94 
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Department of Cardiothoracic Surgery, University Hospital Rigshospitalet, Copenhagen, 95 
Denmark) between December 2015 and December 2019, were included. Previous BLVR had 96 
been performed at the institutions or elsewhere. Repeated LVR were considered, when 97 
previous LVR was assessed to be unsuccessful (primary failure) according to the 98 
multidisciplinary emphysema board or initial benefit had faded over time (secondary failure). 99 
In- and exclusion criteria for LVRS were described previously (16, 17) and were similar in both 100 
study centers.  101 
As many patients were referred from other centers, indications for EBV were not always 102 
according to our own policy and our usual emphysema board protocol. However, institutional 103 
guidelines from both study centers generally read as follows:  104 
Primary scheduled for LVRS:  105 
- bilateral, upper-lobe predominant emphysema 106 
- bulleous or paraseptal emphysema 107 
- concomitant nodule  108 
Primary scheduled for BLVR with valves: 109 
- heterogeneous emphysema markedly involving one whole lobe without collateral 110 
ventilation 111 
- bilateral homogeneous emphysema without collateral ventilation 112 
Absent collateral ventilation must be proven by a interlobar fissure integrity score > 85% 113 
(measured by StratX®, Pulmonx, USA) and a negative Chartis® measurement.  114 
All patients – where both LVRS and BLVR are possible – are fully offered and explained all 115 
alternatives. However, many patients already have their own firm preference. 116 
 117 




(1) Primary EBV non-responder (primary failure): no clinical improvement from beginning to 120 
three months after BLVR despite bronchoscopic revision attempt in case of absent target 121 
atelectasis (i.e. for valve re-placement);  122 
(2) Secondary EBV non-responder (secondary failure): loss of benefit after initial subjective 123 
and objective improvement following BLVR (with and without target lobar atelectasis). The time 124 
interval between BLVR and the time of “secondary failure” was only driven by the patient’s 125 
decision to announce subjective loss of the initial benefit.  126 
 127 
Patients with high-flow fistula after BLVR who thereafter received surgery for combined fistula 128 
closure and LVRS (during the same hospitalization), were analyzed separately.  129 
 130 
Decisions to remove EBVs prior to LVRS depended on presence of target atelectasis (absent 131 
target lobe atelectasis triggered indication to remove EBVs, whereas left in place in case of 132 
evidence of atelectasis).  133 
Surgery and perioperative phase 134 
Preoperatively, all potential LVRS patients were functionally assessed with spirometry and 135 
bodyplethysmography. For cardiac evaluation, a transthoracic echocardiogram was performed 136 
for screening for pulmonaly hypertension. If systolic pulmonary arterial pressure, exceeds 137 
35mmHg, patients are further assessed with right heart catheterization. If mean pulmonary 138 
pressure exceeds 35mmHg, they are usually excluded from LVRS.  139 
LVRS target zones were selected by using CT scans, perfusions scans, densitometries and 140 
intraoperative emphysema appearance. The area with most destruction in heterogeneous 141 
emphysema was approached in cases without persisting atelectasis and without functional 142 
valves in situ, respectively. In patients with persistent atelecatasis and therefore valves left in 143 
situ, a target zone on the contralateral side was searched imperatively.  144 
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LVRS was performed by video-assisted thoracoscopic surgery (VATS) or exceptionally by 145 
anterolateral thoracotomy in case of severe pleural adhesions. Pulmonary resection was 146 
performed with standard staplers and 1-2 chest tubes were placed applying suction with 2 – 5 147 
cm H20. All patients were extubated in the OR and transferred to intensive care or intermediate 148 
care units.  149 
 150 
Follow-up and outcome measures  151 
Follow-up of pulmonary function fests (PFTs) was scheduled at 3 months postoperatively.  152 
Primary outcome measures were improvement of forced expiratory volume in first second 153 
(FEV1) and residual volume (RV). Secondary endpoints included length of hospital stay (LOS), 154 
chest tube time, postoperative complications and 90-day mortality. 155 
 156 
Statistical analysis 157 
Descriptive statistics were used to summarize patients’ characteristics. Normality was 158 
assessed using the Shapiro-Wilk test. Normally distributed continuous variables were reported 159 
as mean and standard deviation (SD) and compared using two-sample independent t-tests. 160 
Non-normally distributed continuous variables were reported as median and range and for 161 
comparisons between two groups the Mann Whitney U test was used. Paired continuous 162 
variables were compared using paired-samples t-test. Categorical variables were summarized 163 
as frequencies (%) and compared using Pearson’s chi-squared test or Fisher’s Exact test 164 
where applicable. 165 
 166 
Results  167 
Thirty-eight patients were included (figure 1). Four patients had persistent pneumothorax with 168 
high-flow fistula even after removal of EBVs. Nineteen patients were primary EBV non-169 
responders despite previous bronchoscopic revision (group 1), and 15 patients had secondary 170 
failure (group 2). Both groups were further divided into subgroups dependent on the presence 171 
8 
 
of target atelectasis. Five patients were primary EBV non-responders despite the presence of 172 
a target atelectasis compared to 14 patients without atelectasis. In group 2, three patients had 173 
loss of effect despite a persistent atelectasis after initially successful EBV treatment, and 12 174 
patients with both loss of effect and atelectasis. EBVs were removed prior to LVRS in all 175 
patients without evidence of atelectasis. In those with persistent atelectasis (n=8), EBVs were 176 
removed in three patients attributed to group 1. In patients with secondary failure and 177 
persistent atelectasis (n=3), EBVs were not removed and LVRS was performed contralateral. 178 
 179 
LVRS outcome in patients with primary or secondary failure after previous EBVs (n=34) 180 
Nineteen patients were female (55.9%). Thirty patients had a VATS procedure (88.24%), while 181 
four patients had VATS converted to a thoracotomy due to adhesions. Median LOS was 8 days 182 
(interquartile range (IQR) 6-13) . Median chest tube time was 5 days (IQR 3-11). Ten patients 183 
(29.4 %) had prolonged air leak longer than 7 days, and one patient had revision surgery for 184 
fistula closure (2.9%). One patient had a pneumothorax after chest tube removal and needed 185 
a new chest drain. No other relevant postoperative complications occurred. Ninety-day 186 
mortality after LVRS was zero.  187 
Pre- and postoperative values of PFTs are displayed in Table 1. Median time interval between 188 
BLVR and LVRS was 10 months (IQR 6-14.25).  189 
 190 
LVRS outcome comparing patients operated for primary failure (n=19) vs secondary failure 191 
(n=15) 192 
There was no significant difference of LOS (9 versus 7 days), chest tube time (6 versus 4 days) 193 
and proportion of patients with prolonged air leak (43% versus 20%) between group 1 and 2. 194 
However, improvement of PFT values between pre- and post LVRS was more pronounced in 195 
group 1 (Table 2). Median time interval between BLVR and LVRS in patients with primary 196 
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failure (9 months, IQR 5-13) did not differ significantly from patients with secondary failure 197 
(median 12 months, IQR 7-16), p = 0.286.  198 
 199 
LVRS outcome in patients treated with EBVs but without achieving a lobar atelectasis  200 
Concerning patients with absent atelectasis, there were no significant differences in LOS, 201 
chest tube time, and proportion of prolonged air leak between the 14 patients with primary 202 
failure compared to the 12 patients in group 2. Again, improvement of PFT values was distinctly 203 
better in the primary failure group (Table 3). Median time interval between BLVR and LVRS in 204 
patients with primary failure (9 months, IQR 4.75-13.5) did not differ significantly from patients 205 
with secondary failure (11.5 months, IQR 6.25-15.75), p = 0.494. 206 
 207 
LVRS outcome in patients with (persistent) lobar atelectasis after EBVs (primary or 208 
secondary failure, n=8) 209 
There were eight patients with (persistent) atelectasis. Of these, EBVs were removed prior to 210 
LVRS in three patients, but in five patients EBVs were left in situ and LVRS was performed at 211 
the contralateral side. In all eight patients, there were no anaesthesiological or perioperative 212 
complications. Median LOS was six days (IQR 4-14 days) and a median chest tube time of 213 
three days (IQR 2-12 days). Three had a prolonged air leak (37.5%). At three months 214 
postoperatively, there was only a significant improvement of RV and RV/TLC, respectively, but 215 
not in FEV1 (Table 4). In patients who had EBVs removed before LVRS (n=3), median LOS 216 
was 15 days (range 6-20), and median chest tube time was 12 days (range 1-17). Two patients 217 
had a prolonged air leak. FEV1 improved from median 840 ml (540-1370) to 1140 ml (730-218 
1550). Preoperative median RV was 3790 ml (value only known for n=1 patient), postoperative 219 
median RV was 3795 ml (range 2900-4690ml)..  220 
In patients who did not have EBVs removed and received contralateral LVRS (n=5), median 221 
LOS was 5 days (range 2-11), and median chest tube time was 3 days (range 2-10). One 222 
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patient had a prolonged air leak FEV1 improved from median 785 ml (range 640-1190) to 880 223 
ml (range 780-1120). RV decreased from median 4475 ml (range 4210-5450) to 3830 (3360-224 
4890). 225 
Median time interval between BLVR and LVRS was 11 months (IQR 8.25-14).  226 
 227 
Outcome of patients with high-flow fistula (n=4) 228 
Four patients with immediate pneumothorax after BLVR with EBVs developed a high-flow 229 
fistula. EBVs were removed during the same hospitalization (after a median of 11 days after 230 
BLVR, IQR 4.5-15.3), followed by VATS. All patients had a fistula at the non-target lobe, which 231 
was closed surgically. At the same time, LVRS was performed at the target lobe. Median 232 
postoperative LOS was 10.5 days (range 7 – 45). Median chest tube time was 19 days (range 233 
2- 43) with one patient having a postoperative chest tube time of 43 days and a second patient 234 
of 30 days, respectively. One 63-year old female patient died because of suicide during in-235 
patient rehabilitation two weeks after LVRS. One 58-year old male patient reported no benefit 236 
at three months postoperatively. Complete pre- and postoperative PFTs were only available in 237 
two patients. Mean FEV1 increased from 550 ml (± 210 ml)) to 700 ml (±141 ml) and RV 238 
increased from 5470ml (± 720) to 6070ml (± 1725ml). DLCO decreased from 25 % (±5%) 239 
predicted to 21 % (±5.8%) predicted. 240 
 241 
Discussion 242 
This retrospective study aimed at investigating the postoperative outcome of patients who 243 
underwent LVRS after previous BLVR who despite initial success deteriorated or who were 244 
unsuccessful immediately after EBV treatment.  245 
LVRS in this sequence is not ideal and has to be considered as salvage therapy. Key issues 246 
of a successful LVRS includes many aspects but selecting the right volume and the right target 247 
area for resection in balance with physiologic parameters is of paramount importance. After 248 
11 
 
EBVs, a lobar atelectasis may be present and valves may be still in place causing disturbance 249 
of bronchial secret clearance. Both leads to compromises in LVRS treatment. Despite this, the 250 
presented data show that the procedure can be offered in some patients without ninety-day 251 
mortality and a significant improvement in lung function. This information is important for 252 
interdisciplinary emphysema-boards counseling patients. Patients must know, that LVRS after 253 
EBV might still be possible but is not equally effective than performed at first choice. The 254 
concept of LVRS and EBV are distinctly different despite the common goal of reducing 255 
hyperinflation of emphysematous lungs. 256 
 257 
EBVs have been shown to be an effective and safe LVR procedure in several randomized 258 
controlled trials (6, 18-20). Improvement of FEV1 by 17% - 29.3% from baseline can be 259 
expected (5, 6, 18, 19, 21). Considering FEV1, there is a responder rate ranging between 47% 260 
at three months and 59% at six months (6, 18). There are several reasons for an unsuccessful 261 
EBV treatment, which can be classified as primary failure or as fading effect over time 262 
(secondary failure). While insufficient data is available on reasons for primary failure, there are 263 
several reported reasons for loss of efficacy over time. According to one-year follow-up data 264 
from the STELVIO trial, permanent removal of EBVs was required in 17% of the patients (22). 265 
Reasons included recurrent pneumothorax, torsion of bronchus, pneumonia, and granulation 266 
tissue. Besides other factors, the latter is maybe leading to paravalvular leakage and 267 
subsequent loss of atelectasis.  268 
In both our study centers, patients who failed to develop an atelectasis or showed a loss of 269 
atelectasis after EBVs usually received revision bronchoscopy at one to three months after 270 
initial BLVR. Those who still had no profit despite of EBV replacement were discussed at the 271 
multidisciplinary emphysema board. Performing LVRS in some of these, there was a significant 272 
improvement of PFT values at three months, which was more distinct in patients with primary 273 
failure after EBV treatment. Furthermore, there is a tendency that patients, undergoing 274 
unplanned LVRS due to high-flow fistula after EBV treatment, might have a poor outcome.  275 
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Compared to primary LVRS with a reported improvement of FEV1 between 41% and 73% (23-276 
26), efficiency of LVRS in patients with previous EBV therapy seems inferior. However, our 277 
study was not designed to answer this specific question, and comparison to historical LVRS 278 
cohorts is not without challenges. At least, postoperative morbidity and mortality seems 279 
comparable to primary LVRS. 280 
Usually, target lobe atelectasis after EBVs is a good indicator for a favorable outcome with 281 
improvements of dyspnea, quality of life, 6-MWD and PFT values (27). However, in this study, 282 
we found eight patients with unsuccessful EBV treatment in spite of an existing target lobe 283 
atelectasis. Reasons for these rare cases are not completely understood. Certainly, indications 284 
for EBVs (in particular hyperinflation) must be reviewed. The question arises, if EBVs should 285 
be removed or left in situ prior to LVRS in these cases. Interestingly, all patients with persistent 286 
atelectasis but loss of clinical benefit from EBVs improved after LVRS in FEV1 and RV. 287 
According to our experience, these patients can be safely treated with contralateral LVRS, 288 
leaving EBVs in situ. Conceptually, this corresponds to results from previous studies 289 
concerning Re-LVRS, and as such, the fading benefit after EBVs reflects the natural course of 290 
pulmonary emphysema (11, 14, 28). The questions remains open, if valves should be removed 291 
prior to LVRS.  A total lobar atelectasis is a relevant intervention into the physiology of a patient 292 
with advanced emphysema. Lobectomy performed during LVRS should be reserved only to 293 
the rare cases of a total lobar destruction. In all our cases, better preserved lung parenchyma 294 
was left in place. If valves would be removed and the totally atelectatic lung would re-expand 295 
including the functioning lung parenchyma, a more balanced remodeling by LVRS would be 296 
possible (29).  297 
However, in patients with absent atelectasis, improvement was only significant in those with 298 
primary failure. This is surprising, since patients with secondary failure had experienced a 299 
temporary benefit after EBV treatment and thus, the principle of LVR was proven to succeed 300 
in these patients. Maybe in patients with secondary failure, the natural course of emphysema 301 
already was too advanced and prevented any LVR procedure to be beneficial again. According 302 
to our experience from this retrospective and heterogeneous data, EBV removal and 303 
13 
 
subsequent LVRS is a promising option in patients with primary failure after previous EBV 304 
therapy.  305 
Time interval between BLVR and LVRS did not differ significantly between patients with 306 
primary failure and those with secondary failure. Only in patients with primary failure, the 307 
decision for a further intervention usually was already made three months after BLVR. In 308 
patients with secondary failure, this decision was dependent on patient’s subjective loss of 309 
benefit. Altogether, including planning time for LVRS and several other patient factors, this 310 
finding might be coincidental. 311 
Pneumothorax occurs in about 15-30% of patients after BLVR with EBVs, which is usually 312 
treated with a chest tube drainage (5, 18, 30). In almost 70% of cases, these patients have a 313 
prolonged air leak continuing longer than seven days (30). In our study, there were four 314 
patients with persistent high-flow fistula despite previous EBV removal, as recommended (2). 315 
In these patients, fistula closure by VATS followed by LVRS at the former EBV target lobe was 316 
performed. The outcome was poor. Although firm conclusions are not possible based on our 317 
small experience, combined fistula closure and LVRS might not be recommendable. Probably, 318 
a staged procedure is preferable.  319 
There are some limitations to this study, essentially due to its retrospective nature and the 320 
relatively small and heterogeneous group of patients. Quality of EBV therapy was not 321 
assessed, and the definition of failure was not quantitative, thus, only assessed by patient’s 322 
statements. Additionally, outcome of LVRS after EBV was only described by morbidity, 323 
mortality and PFTs, missing i.e. 6-MWD or quality of life. Maximum benefit after LVRS is 324 
usually reached after 3-6 months, whereas our data only consist of 3-month follow-up.  325 
The small patient’s number in this study might be sufficient to point out the favorable outcome 326 
of LVRS after previous EBVs, while the conclusions drawn from the subgroup analyses might 327 





LVRS after previous BLVR with EBVs shows low morbidity, no mortality and significant clinical 331 
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1: figure legend: 354 
Figure 1: Flow chart of patients undergoing LVRS after previous BLVR using EBVs 355 
(n=38). BLVR, bronchoscopic lung volume reduction; LVRS, lung volume reduction 356 
surgery 357 
 358 
Figure legend for Central image:  359 
Bilateral, upper-lobe predominant emphysema: coronar CT scan (left upper corner), 360 
sagittal densitometry of the right lung (right upper corner), endobronchial valve in situ 361 
















Table 1 376 
  Mean (± SD) pre-LVRS 3 months post 
LVRS 
p-value 
FEV1, ml  640 (± 210) 
(n=32) 
720 (± 141.1) 0.011 
FEV1, % predicted  23 (± 3.6) 
(n=34) 
29.7 (± 6.4) 0.010 
TLC, ml  7661.4 (± 1853.3) 
(n=26) 
7599.6 (± 1782.8) 0.22 
TLC, % predicted  137.4 (± 23.8) 
(n=27) 
130 (± 18.0) 0.12 
RV, ml  6070 (± 1725.3) 
(n=27) 
5180 (± 720.2) 0.014 
RV, % predicted  272 (± 80.6) 
(n=26) 
238.7 (± 20.1) 0.004 
RV/TLC  0.73 (± .011) 
(n=29) 
0.70 (± 0.17) 0.002 
DLCO, % predicted  25 (± 5) 
(n=34) 
23.3 (± 5.8) 0.043 
 377 
Table 1: Pulmonary function tests pre- and post-LVRS in patients with primary and secondary EBV 378 
failure (n=34). FEV1 = forced exspiratory volume in 1 second, TLC = total lung capacity, RV = residual 379 




Table 2 382 
  Primary failure (n = 19)   Secondary failure (n=15)   
  Mean (± 
SD) 








FEV1, ml  752.9 (± 303.9) 
(n=17) 
871.9 (± 306.8) 
(n=16) 
0.003 689.3 (± 220) 
(n=15) 





26 (± 8.4) 
(n=19) 
31.3 (± 9.1) 
(n=17) 
0.002 26.9 (± 11.6) 
(n=15) 
28.9 (± 9.6) 
(n=13) 
0.77 















143.8 (± 25.1) 
(n=13) 
136.7 (± 20.5) 
(n=14) 
0.39 131.0 (± 21.4) 
(n=13) 
122.3 (± 10.7) 
(n=12) 
0.21 













259.1 (± 57) 
(n=13) 
227.2 (± 54.5) 
(n=14) 
0.20 231.3 (± 43) 
(n=13) 
207.8 (± 42.8) 
(n=12) 
0.021 
RV/TLC 0.70 (± 0.04) 
(n=16) 
0.63 (± 0.06) 
(n=15) 
0.044 0.69 (± 0.06) 
(n=13) 







36.2 (± 11.6) 
(n=16) 
0.15 32.76 (± 12.31) 
(n=15) 




Table 2: Pulmonary function tests in patients with primary failure (n=19) and in patients with secondary 384 
failure (n=15).  FEV1 = forced exspiratory volume in 1 second, TLC = total lung capacity, RV = 385 
residual volume, DLCO = diffusion capacity, ml = milliliter, SD = standard deviation 386 
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Table 3 387 
  primary failure, no atelectasis (n = 14) secondary failure, never or loss of 
atelectasis (n=12) 
  Mean (± 
SD) 
pre LVRS 3 months post 
LVRS 
p-value  pre LVRS 3 months post 
LVRS 
p-value 
FEV1 ml 723.8 (± 291.6)  
(n=13) 
827.7 (± 274.6) 
(n=13) 
0.045 631.7 (± 180.2) 
(n=12) 
678 (± 149.7) 
(n=10) 
0.60 
FEV1 % 26.1 (± 9.2) 
(n=14) 
30.4 (± 9.7) 
(n=13) 
0.029 25.6 (± 11.1) 
(n=12) 
28 (± 9.3) 
(n=10) 
0.74 














TLC % 149.3 (± 23.3) 
(n=11) 
143.1 (± 17.9) 
(n=11) 
0.44 134.1 (± 23.0) 
(n=10) 
123.3 (± 11.4) 
(n=10) 
0.28 
RV ml 5327.2 (± 
2598.2) 
(n=12) 
4364.4 (± 2653) 
(n=11) 
0.030 
4825 (± 1427.7) 
(n=10) 
4471 (± 1354.4) 
(n=10) 
0.084 
RV % 271.3 (± 53) 
(n=11) 
241.3 (± 50.7) 
(n=11) 
0.20 236.5 (± 48.1) 
(n=10) 
212.1 (± 45.5) 
(n=10) 
0.08 
RV/TLC 70.3 (± 4.2) 
(n=12) 
65.1 (± 6.5) 
(n=11) 
0.15 70.4 (± 6) 
(n=10) 
65.7 (± 7.8) 
(n=10) 
0.18 
DLCO 30.6 (± 11.2) 
(n=14) 
37 (± 12.4) 
(n=13) 
0.013 29.4 (± 10.2) 
(n=12) 




Table 3: Pulmonary function tests in patients with primary failure and no atelectasis (n=14) and in 389 
patients with secondary failure and never or loss of atelectasis (n=12). FEV1 = forced exspiratory 390 
19 
 
volume in 1 second, TLC = total lung capacity, RV = residual volume, DLCO = diffusion capacity, ml = 391 
milliliter, SD = standard deviation 392 
 393 
Table 4 394 
   Mean (± SD) pre LVRS 3 months post 
LVRS 
p-value 
FEV1 ml  878.6 (± 300.1) 
(n=7) 
990 (± 306) 
(n=6) 
0.071 
FEV1 % 28 (± 9.9) 
(n=8) 
33.1 (± 8.8) 
(n=7) 
0.12 
TLC ml 6567.5 (± 1119.5) 
(n=5) 
6330 (± 1282.5) 
(n=5) 
0.24 
TLC % 117.6 (± 9.2) 
(n=5) 
114.7 (± 7.2) 
(n=5) 
0.26 
RV ml 4480 (± 622.7) 
(n=5) 
3934 (± 850.7) 
(n=5) 
0.013 
RV % 205.3 (± 16.2) 
(n=5) 
179.9 (± 28.8) 
(n=5) 
0.007 
RV/TLC 67.6 (± 5) 
(n=7) 
58.4 (± 3) 
(n=6) 
0.004 
DLCO 37.9 (± 15.3) 
(n=8) 




Table 4: Pulmonary function tests in patients with (persistent) atelectasis after BLVR (primary or 396 
secondary failure, n=8).  397 
20 
 
FEV1 = forced exspiratory volume in 1 second, TLC = total lung capacity, RV = residual volume, 398 
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